Drug Trial Radar · NCT00287183
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Last checked: Nov 19, 2026Latest source record: Oct 1, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Feb 2006
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 31 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488 to patients with diabetic nephropathy.
Conditions
- Diabetic Nephropathy
Interventions
PF-04494700 (TTP488)Drug
60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary endpoint of efficacy will be assessed by comparing the treatment groups based on the change in urinary albumin-creatinine ratio (UACR)Time frame: from baseline to end of treatment (Month 6).
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Red Deer, Alberta, Canada
Pfizer Investigational Site
Penticton, British Columbia, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Burlington, Ontario, Canada
Pfizer Investigational Site
Courtice, Ontario, Canada
Pfizer Investigational Site
Fort Erie, Ontario, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
Kitchener, Ontario, Canada
Pfizer Investigational Site
Kitchener, Ontario, Canada
Pfizer Investigational Site
Millon, Ontario, Canada
Pfizer Investigational Site
North Bay, Ontario, Canada
Pfizer Investigational Site
Oakville, Ontario, Canada
Pfizer Investigational Site
Saint Catherines, Ontario, Canada
Pfizer Investigational Site
Scarborough Village, Ontario, Canada
Pfizer Investigational Site
Smith Falls, Ontario, Canada
Pfizer Investigational Site
Thornhill, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.